IN172427B - - Google Patents

Info

Publication number
IN172427B
IN172427B IN954CA1990A IN172427B IN 172427 B IN172427 B IN 172427B IN 954CA1990 A IN954CA1990 A IN 954CA1990A IN 172427 B IN172427 B IN 172427B
Authority
IN
India
Prior art keywords
stable
biologically active
complexes
gangliosides
beta
Prior art date
Application number
Other languages
English (en)
Inventor
Francesco Della Valle
Aurelio Romeo
Lanfranco Callegaro
Original Assignee
Fidia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT04855589A external-priority patent/IT1238347B/it
Application filed by Fidia Spa filed Critical Fidia Spa
Priority to IN954CA1990 priority Critical patent/IN172427B/en
Priority to CA002029965A priority patent/CA2029965A1/en
Priority to DE69019122T priority patent/DE69019122T2/de
Priority to AT90403221T priority patent/ATE122056T1/de
Priority to CN90110048A priority patent/CN1052868A/zh
Priority to JP2310148A priority patent/JPH03179000A/ja
Priority to EP90403221A priority patent/EP0433113B1/en
Priority to AU66628/90A priority patent/AU629714B2/en
Publication of IN172427B publication Critical patent/IN172427B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
IN954CA1990 1989-11-14 1990-11-13 IN172427B (ja)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IN954CA1990 IN172427B (ja) 1989-11-14 1990-11-13
CA002029965A CA2029965A1 (en) 1989-11-14 1990-11-14 Stabilization and maintenance of the nerve growth factor biological activity by use of natural gangliosides or derivatives thereof
DE69019122T DE69019122T2 (de) 1989-11-14 1990-11-14 Stabilisierung und Wartung der biologischen Aktivität des Nervenwachstumsfaktor unter Benützung von natürlichen Gangliosiden oder deren Derivaten.
AT90403221T ATE122056T1 (de) 1989-11-14 1990-11-14 Stabilisierung und wartung der biologischen aktivität des nervenwachstumsfaktor unter benützung von natürlichen gangliosiden oder deren derivaten.
CN90110048A CN1052868A (zh) 1989-11-14 1990-11-14 利用天然神经节苷脂或其衍生物来稳定并维持神经生长因子的生物学活性
JP2310148A JPH03179000A (ja) 1989-11-14 1990-11-14 天然のガングリオシドまたはその誘導体を用いる神経成長因子の生物学的活性の安定化および維持
EP90403221A EP0433113B1 (en) 1989-11-14 1990-11-14 Stabilization and maintenance of the nerve growth factor biological activity by use of natural gangliosides or derivatives thereof
AU66628/90A AU629714B2 (en) 1989-11-14 1990-11-14 Stabilization and maintenance of the nerve growth factor biological activity by use of natural gangliosides or derivatives thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT04855589A IT1238347B (it) 1989-11-14 1989-11-14 Stabilizzazione e mantenimento dell'attivita' biologica del fattore di crescita nervoso mediante gangliosidi naturali o loro derivati.
IN954CA1990 IN172427B (ja) 1989-11-14 1990-11-13

Publications (1)

Publication Number Publication Date
IN172427B true IN172427B (ja) 1993-07-24

Family

ID=26324373

Family Applications (1)

Application Number Title Priority Date Filing Date
IN954CA1990 IN172427B (ja) 1989-11-14 1990-11-13

Country Status (8)

Country Link
EP (1) EP0433113B1 (ja)
JP (1) JPH03179000A (ja)
CN (1) CN1052868A (ja)
AT (1) ATE122056T1 (ja)
AU (1) AU629714B2 (ja)
CA (1) CA2029965A1 (ja)
DE (1) DE69019122T2 (ja)
IN (1) IN172427B (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
IT1259176B (it) * 1992-10-23 1996-03-11 Fidia Spa Composizioni farmaceutiche comprendenti monosialoganglioside gm1 (o suo derivato) e fattore neuronotrofico ciliare (cntf) atte al trattamento di patologie del sistema nervoso
FR2703682B1 (fr) * 1993-04-06 1995-05-12 Atochem Elf Sa Procédé de préparation de (méth)acrylate(s) d'alkylimidazolidone.
CN1046734C (zh) * 1995-03-24 1999-11-24 中国科学院上海生理研究所 一种含神经节苷脂为主的糖脂类物质的生产方法
CN103083724A (zh) * 2013-01-31 2013-05-08 东华大学 一种负载gm1和ngf双营养因子的神经组织修复支架的制备方法
US10709770B2 (en) 2013-07-31 2020-07-14 Mead Johnson Nutrition Company Nutritional compositions containing a prebiotic and lactoferrin and uses thereof
US9609888B2 (en) 2013-07-31 2017-04-04 Mead Johnson Nutrition Company Nutritional compositions containing synergistic combination and uses thereof
US10617701B2 (en) 2015-07-10 2020-04-14 Mead Johnson Nutrition Company Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
US10582714B2 (en) 2015-07-10 2020-03-10 Mead Johnson Nutrition Company Nutritional compositions and methods for promoting cognitive development
CN108498523B (zh) * 2017-02-24 2023-06-20 上海交通大学 含不饱和脂肪酸链的神经节苷脂衍生物的制备方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4716223A (en) * 1981-08-04 1987-12-29 Fidia, S.P.A. Method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions
IT1199116B (it) * 1984-07-03 1988-12-30 Fidia Farmaceutici Derivati di gangliosidi
IT1219839B (it) * 1988-02-08 1990-05-24 Fidia Farmaceutici Purificazione,caratterizazione e applicazione di un fattore neuronotrofico derivato da cervello di nammifero
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle

Also Published As

Publication number Publication date
EP0433113B1 (en) 1995-05-03
DE69019122T2 (de) 1995-10-05
CA2029965A1 (en) 1991-05-15
CN1052868A (zh) 1991-07-10
EP0433113A1 (en) 1991-06-19
JPH03179000A (ja) 1991-08-02
ATE122056T1 (de) 1995-05-15
AU629714B2 (en) 1992-10-08
AU6662890A (en) 1991-05-23
DE69019122D1 (de) 1995-06-08

Similar Documents

Publication Publication Date Title
IL90949A0 (en) Fr901228 substance,processes for the preparation thereof and pharmaceutical compositions containing the same
GB8927546D0 (en) Process for the production of biologically active tgf-beta
UA32512C2 (uk) Похідні ксантину, спосіб їх одержання, та фармацевтична композиція
HUT48247A (en) Process for producing aza-bicyclo-octyl-ether derivatives and pharmaceutical compositions containing them as active components
IN172427B (ja)
HUT46709A (en) Process for producing cyclic peptides and pharmaceutical compositions containing them as active components
ZA934037B (en) Novel biologically active eburnamenine derivatives, pharmaceutical compositions containing them and process for preparing same.
HUT51596A (en) Process for production of the active substance of the medical composition levodopa
HUT48251A (en) Process for producing new xantin derivatives and pharmaceutical compositions containing them as active components
HUT46224A (en) Process for producing pharmaceutical compositions containing prostaglandin e1-derivatives
HUT41784A (en) Process for producing 1,8-naphtiridine derivatives and pharmaceutical compositions containing them as active agents
HUT45537A (en) Process for producing delta-22 derivatives of ll-f 28249 compounds and pharmaceutical compositions containing them as active components, and insecticide compositions
HUT51284A (en) Process for production of epipodofillotoxin glucozides substituated by fluor and medical compositions containing them as active substance
HUT45249A (en) Process for producing 6,7,8,9-tetrahydro-10-methylpyrido/1,2-a/indol-9-amines, theyr derivatives and pharmaceutical compositions containing them as active components
HUT48642A (en) Process for producing amino-acid derivatives and pharmaceutical compositions containing them as active components
HUT47096A (en) Process for producing 1,2-dithiol-3-thion derivatives and pharmaceutical compositions containing them as active components
HUT49320A (en) Process for producing ornithine derivatives and pharmaceutical compositions containing them as active components
HUT50762A (en) Process for production of medical compositions containing as active substance derivatives of pirrol and process for production of the active substance
HUT53113A (en) Process for production of hindering tumour platina (iv) diamin komplex and medical compositions containing them as active substance
HUT47902A (en) Process for producing anilino-phenyl-thiourea-, -isothiourea- and -carbodiimid derivatives and insecticide compositions containing them as active components
HUT48885A (en) Process for producing nukleotid-analogues and pharmaceutical compositions containing them as active components
HUT52522A (en) Process for producing imidazol-substituted peptide derivatives and pharmaceutical compositions containing them as active components
HU908403D0 (en) Process for the production of amino-pyridinyl-methanol- and amino-methyl-pyridine-amin derivatives and medical compositions containing them as active agents
HUT47020A (en) Process for production of stabilly injectable medical compounds containing as active substance 1,4-dihidroxi-5,8-bis/2/2-hidroxi-ethil-amin/-ethil-amin-antraquinon-dihydrochlorid
HUT49145A (en) Process for production of 14,15 substituated ianosterins and medical compositions containing them as active substance